Tag: Pharmaceuticals

This piece discusses pharmaceutical product reformulations and product hopping strategies, along with the impact that antitrust scrutiny may have on innovation incentives. The main...

By James Killick, Assimakis Komninos & Aqeel Kadri (White & Case LLP)1   Introduction On March 10, 2020, the UK Court of Appeal upheld the Competition Appeal...

By James Killick, Marc Israel, Jérémie Jourdan & Aqeel Kadri (White & Case LLP)1 On January 30, 2020 (just sneaking in before Brexit), the European...

B The pharmaceutical and medical products industry in China has seen high levels of antitrust enforcement activity from 2015 onwards. This article takes stock of...

Maria José Schmidt-Kessen (Copenhagen Business School)1   Introduction While we are still awaiting the judgments in the pending appeals on pay-for-delay settlements in Lundbeck2 and Servier,3 the...

Jan Blockx (University of Antwerp)1 Introduction Twelve years ago, on January 15, 2008, the European Commission used its power to conduct unannounced inspections in a sector...

US biotech company Celgene has agreed to pay a US$55 million settlement after it was accused of illegally maintaining a monopoly over the market...

Roche and Spark Therapeutics’ road to a US$4.3 billion merger has been a rocky one, with various delays pushing the long-gestating agreement back four...

February 2019 CPI EU News Column edited by Thibault Schrepel, Sam Sadden & Jan Roth (CPI) presents: What the Servier judgment1 teaches us about market definition under...

January 2019 CPI Europe Column edited by Anna Tzanaki (Competition Policy International) & Juan Delgado (Global Economics Group) presents: Excessive Pricing in Pharmaceutical Markets By Pedro Caro de Sousa (OECD)1 Introduction This...